IMRX News & Events

Immuneering Corporation announced that updated data from the Phase 2a clinical trial evaluating atebimetinib, IMM-1-104, in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients will be presented as an oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting, taking place May 29 - June 2, 2026, in Chicago, IL. The oral presentation will highlight data from an expanded cohort totaling 55 first-line patients, which includes the initial cohort of 34 patients that the company previously reported plus an additional 21 patients. "We are excited to present new survival data from an expanded cohort of 55 first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP in an oral presentation at ASCO," said Ben Zeskind, Ph.D., CEO of Immuneering. "Atebimetinib was designed with three distinct mechanisms to promote survival: shrinking tumors durably, preserving body mass, and maximizing tolerability."

Immuneering announced the presentation of new genetic data at the 2026 American Association for Cancer Research, AACR, Annual Meeting taking place April 17-22, 2026 in San Diego, CA. Key Findings from the AACR Presentation: Rare MAPK pathway reactivation: Across 86 patients treated with atebimetinib monotherapy and 37 patients treated in combination with chemotherapy, emergent and acquired mutations rarely converged on the RAS/MAPK pathway, in contrast to what is commonly observed with chronic RAS-targeted therapies. Diffuse, non-convergent resistance patterns: Emergent resistance following atebimetinib treatment utilized a variety of non-MAPK pathways, rather than converging on a single escape mechanism. Limited early adaptive resistance: ctDNA analysis showed minimal early molecular evolution during treatment, indicating that atebimetinib is not driving adaptive resistance and may impose less selective pressure than continuous pathway inhibition. Taken together, the data position atebimetinib as a differentiated MEK inhibitor with potential to drive deep and durable antitumor activity.

Stocks had a down Friday to close out a down week after data showed unexpected job cuts and rising unemployment in February. Nonfarm payrolls fell by 92,000 in February, missing the growth of 55,000 that economists predicted, and the unemployment rate rose to 4.4% from 4.3%. Meanwhile, West Texas Intermediate futures broke above $90 per barrel for first time since October 2023 after President Donald Trump said in a Truth Social post that there won't be a deal to end the U.S.-Iran war without an "unconditional surrender."Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:President Trump and Secretary Hegseth met with the CEOs of defense companies today at the White House asthere "will be no deal with Iran except unconditional surrender"Marvellreceived a pair of upgrades and a number of price target hikes from Wall Street firms after itswere strongJPMorgan says Costco's"core story remains intact" following the membership club retailer'sGapshares traded lower after Old Navy and Athletain Q4Day One Biopharmaceuticalsby Servier for $21.50 per share in cash2. WALL STREET CALLS:Marvellwasto Buy at Benchmark and BofA on expectations for accelerating data center demandKarmanto Overweight at Piper SandlerOktato Outperform at BMO CapitalWedbushTrade Deskto Underperform, says impact of OpenAI partnership overestimatedZoetisto Hold from Buy at Nephron Research3. AROUND THE WEB:China near deal to order 500 Boeing737 Max jets, Bloomberg saysStates preparing to challenge planned tie-up of Nexstarwith Tegna, WSJ reportsPrivate equity firms including Blackstoneand TPGhave expressed interest in acquiring Whitestone REIT, Reuters reportsChina has approved Pfizer'sGLP-1 treatment Xianweiying for weight management in adults, Reuters saysMetahired the engineering team from Atma Sciences, the startup that makes the vibe coding app Gizmo, earlier in 2026 to join its Superintelligence Labs, Business Insider reports4. MOVERS:Samsaragained after reportingand providing guidance for Q1 and FY27ASP Isotopesincreased afterQuantum Leap Energy has entered into a non-binding MOU with a large publicly traded U.S. energy companyWestern Alliancedeclined after beingby Jefferies (JEF) that payments of $126.4M owed to the bank pursuant to a forbearance agreement will not be paid as agreedREalloysfell after announcing a 2.7MIngram Microdeclined after announcing a 8.999M5. EARNINGS/GUIDANCE:Algonquin Powersreportedand backed its guidance for FY26Embraerreported, with revenue beating consensusImmuneeringreported, with CEO Ben Zeskind commenting that 2025 was "a transformative year"SunCar Technologyreportedfor Q4Methode Electronicsreported Q3 results andfor FY26INDEXES:The Dow fell 0.95%, or 453.19, to 47,501.55, the Nasdaq lost 1.59%, or 361.31, to 22,387.68, and the S&P 500 declined 1.33%, or 90.69, to 6,740.02.